Skip to main
CTNM
CTNM logo

CTNM Stock Forecast & Price Target

CTNM Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 80%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Contineum Therapeutics Inc. is positioned favorably due to its robust financial foundation, highlighted by cash and equivalents of $190.7 million, which is expected to adequately fund operations through 2027, allowing for the advancement of its promising drug candidates PIPE-791 and PIPE-307. The company's progress in the early stages of clinical trials demonstrates good pharmacokinetics and safety, building confidence as it looks forward to entering Phase II trials in 2025 with backing from an experienced partner. Additionally, the substantial unmet need in multiple sclerosis (MS) indicates that any positive outcomes from the company's candidates could capture significant market interest, enhancing the potential for future growth.

Bears say

Contineum Therapeutics Inc faces significant risks that contribute to a negative outlook for its stock, primarily driven by the potential for developmental setbacks related to its drug candidates, PIPE-791 and PIPE-307. These include the possibility of unexpected safety signals, failure to secure regulatory approvals, and challenges in the commercialization of PIPE-791, particularly given its existing partnership with Johnson & Johnson. Additionally, the company operates without any revenue streams, which raises concerns about its ability to fund ongoing research and development amidst intense competition and operational challenges.

CTNM has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 80% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Contineum Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Contineum Therapeutics Inc (CTNM) Forecast

Analysts have given CTNM a Buy based on their latest research and market trends.

According to 5 analysts, CTNM has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Contineum Therapeutics Inc (CTNM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.